XBIO - Xenetic Biosciences Inc

XBIO - Xenetic Biosciences Inc

https://www.xeneticbio.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Xenetic Biosciences ( XBIO ) Reports Q2 Loss, Misses Revenue Estimates

Zacks Commentary • 1 month ago • score: 0.04

Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of +29.69% and -7.81%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Xenetic Biosciences ( XBIO ) Reports Q2 Loss, Tops Revenue Estimates

Zacks Commentary • 1 year, 1 month ago • score: 0.10

Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of 0% and 34.44%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Xenetic Biosciences Reports Q1 Loss, Misses Revenue Estimates - Xenetic Biosciences ( NASDAQ:XBIO ) , Affimed ( NASDAQ:AFMD )

Benzinga • 1 year, 4 months ago • score: 0.08

Xenetic Biosciences XBIO came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.60 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of ...

Xenetic Biosciences ( XBIO ) Reports Q1 Loss, Misses Revenue Estimates

Zacks Commentary • 1 year, 4 months ago • score: 0.11

Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of 1.27% and 21.39%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Xenetic Biosciences, Inc., a biopharmaceutical company, is focused on advancing XCART, a customized chimeric antigen receptor T (CAR T) platform technology designed to target patient-specific tumor neoantigens. The company is headquartered in Framingham, Massachusetts.

52W High

$5.27

52W Low

$2.20

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

2.44

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

1.03

EV/Revenue (<3 favorable)

0.19

P/S (TTM) (<3 favorable)

1.94

P/B (<3 favorable)

1.06

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

19.06%

Institutions (25–75% balanced)

4.60%

Shares Outstanding

1,542,100

Float

1,182,800

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

2,446,200

Gross Profit (TTM)

2,446,200

EPS (TTM)

-2.00

Profit Margin (>10% good)

-1.26%

Operating Margin (TTM) (higher better)

-1.23%

ROE (TTM) (>15% strong)

-0.52%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.19

Momentum

Bearish momentum

Value

0.0500

Previous

-0.0131

Trend

Rising

Signal Cross

Crossed Up Today

As of

Sep. 12, 2025